Published : Jul 2019
Tables : 0
Figures : 0
Category : Healthcare
No. of Pages : 0
Report Code : HC-1142
Global Hemato Oncology Testing Market is estimated to value over USD 4.6 billion by 2029 end and register a CAGR of over 13.8% during the forecast period 2019 to 2029. The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment. Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period. Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits. Global Hemato Oncology Market Regional Insight: The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products. Global Hemato Oncology Market Segmentation: 1. By Region • North America • Europe • Asia Pacific • Rest of the World 2. By Product & Service Type • Services • Assay Kits 3. By Cancer Type • Leukemia • Acute Myeloid Leukemia • Acute Lymphocytic Leukemia • Lymphoma • Non-Hodgkin Lymphoma • Hodgkin Lymphoma • Others 4. By Technology • PCR • NGS • IHC • Cytogenetics • Others Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants Key Market Players: • F. Hoffmann-La Roche Ltd. • Abbott Laboratories • Thermo Fisher Scientific Inc. • Illumine Inc. • Molecular MD • Invivoscribe Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the hemato oncology testing market by region, by product & service type, by cancer type, by technology • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Global Hemato Oncology Testing Market is estimated to value over USD 4.6 billion by 2029 end and register a CAGR of over 13.8% during the forecast period 2019 to 2029.
The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment. Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period.
Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits.
The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products.
1. By Region • North America • Europe • Asia Pacific • Rest of the World
2. By Product & Service Type • Services • Assay Kits
3. By Cancer Type • Leukemia • Acute Myeloid Leukemia • Acute Lymphocytic Leukemia • Lymphoma • Non-Hodgkin Lymphoma • Hodgkin Lymphoma • Others
4. By Technology • PCR • NGS • IHC • Cytogenetics • Others
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
Key Market Players: • F. Hoffmann-La Roche Ltd. • Abbott Laboratories • Thermo Fisher Scientific Inc. • Illumine Inc. • Molecular MD • Invivoscribe Inc.
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the hemato oncology testing market by region, by product & service type, by cancer type, by technology • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
UK : +44 141 628 9353 US : +1 970 279 4295
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics